MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.Investor Call Details:Topics to Be Covered:Register Today: Investors and interested parties are encouraged to register for the webcast in advance.

宾夕法尼亚州马尔文（MALVERN），2024年6月25日（Global NEWSWIRE）--通过IBN-Annovis Bio Inc.（纽约证券交易所：ANVS）（“Annovis”或“公司”），一家晚期临床药物平台公司，开创了阿尔茨海默氏病（AD）和帕金森氏病（PD）等神经退行性疾病的转化疗法，今天宣布将举办投资者网络广播，讨论其主要候选药物Buntanetap的最新发展和未来计划。投资者通话详细信息：要涵盖的主题：立即注册：鼓励投资者和感兴趣的各方提前注册网络广播。

To register, please visit Webcast Registration and complete the registration form.About Buntanetap: Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases.About Annovis Bio Inc.: Headquartered in Malvern, Pennsylvania, Annovis Bio Inc.

要注册，请访问网络广播注册并填写注册表格。关于Buntanetap：Buntanetap（以前称为Posiphen或ANVS401）通过抑制多种神经毒性蛋白的形成来靶向神经变性，包括淀粉样蛋白β，tau，α-突触核蛋白和TDP43。通过改善突触传递，轴突运输和减少神经炎症，Buntanetap旨在逆转AD，PD和其他神经退行性疾病中的神经变性。关于安诺维斯生物公司：总部位于宾夕法尼亚州马尔文的安诺维斯生物公司。

is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts Forward-Looking StatementsThis press release contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Se.

致力于解决AD和PD等疾病中的神经退行性疾病。该公司的创新方法针对多种神经毒性蛋白，旨在恢复大脑功能并改善患者的生活质量。有关更多信息，请访问www.annovisbio.com，并在LinkedIn、YouTube和X上关注我们。鼓励感兴趣的投资者和股东注册电子邮件警报，以获取新闻稿和行业最新信息https://www.Annovisbio.com/email-alerts前瞻性声明本新闻稿包含经修订的《1933年证券法》第27A节和Se所指的“前瞻性”声明。